Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 3/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.59 |
| ▸ | PPP1CC | P36873 | 3/20 | 0.59 |
| ▸ | FABP7 | O15540 | 4/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.58 |
| ▸ | TFPI2 | P48307 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800576 | 0.95 | FABP7 (0.55) | PPM1BPTPN1PPP1CCFABP7FABP5 | |
| SCHEMBL2032598 | 0.84 | PPM1B (0.56) | PPM1BPTPN1PPP1CCFABP7FABP5 | |
| SCHEMBL31509821 | 0.81 | FABP7 (0.73) | FABP7FABP5TSHRLMNA | |
| SCHEMBL7757018 | 0.81 | FABP7 (0.73) | FABP7FABP5TSHRLMNA | |
| SCHEMBL7756954 | 0.81 | FABP7 (0.73) | FABP7FABP5TSHRLMNA | |
| SCHEMBL7757006 | 0.81 | FABP7 (0.73) | FABP7FABP5TSHRLMNA | |
| SCHEMBL13432587 | 0.81 | FABP7 (0.73) | FABP7FABP5TSHRLMNA | |
| SCHEMBL7756965 | 0.81 | FABP7 (0.73) | FABP7FABP5TSHRLMNA | |
| SCHEMBL12114007 | 0.81 | FABP7 (0.73) | FABP7FABP5TSHRLMNA | |
| SCHEMBL4386438 | 0.80 | ALDH1A1 (0.55) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307344-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8541458-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541458-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541458-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | LIXTE BIOTECHNOLOGY, INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | LIXTE BIOTECHNOLOGY, INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | LIXTE BIOTECHNOLOGY, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8227473-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227473-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227473-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | PPM1B 3573/4885PTPN1 3699/4885PPP1CC 3030/4885 |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | HCCS, OXA1L, OTC | PPM1B 3573/4885PTPN1 3699/4885PPP1CC 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.